Abstract
This study evaluated the performance of the methodology of 100% rapid review on the cervix Pap smears with and without information on clinical risk criteria by using the average time of one and two minutes assays. A total of 5,395 smears were analyzed, and of these 274 were classified as altered and 5,121 as negative after routine examinations. Of negative smears, 958 had clinical risk criteria information, and they were analyzed by rapid review, which identified ten (1.04 %) as altered by the one minute-revision, and nine (0.93) by using a time of two minutes. Analyzing 4,163 negative smears without clinical risk criteria information by rapid review using the times of one and two minutes, 35 (0.84%) were identified as altered in both procedures. The technique of rapid review showed sensitivity of 83% and 75% for the review time of one minute and two minutes, respectively, in smears with available clinical risk criteria information. No difference was found in detecting false-negative smears with and without available clinical risk criteria information. Also, no difference was found in the rapid review performance for detecting false-negative results by employing one to two-minutes techniques.References
1. Cantor SB, Atkinson EN, Cardenas-Turanzas M, Benedet JL, Follen M, MacAulay C. Natural history of cervical intraepithelial neoplasia: a meta-analysis. Acta Cytol. 2005;49(4):405-15.
2. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M. Comparative risk assessment collaborating group (cancers). Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005;366(9499):1784-93.
3. Derchain SFM, Longatto Filho A, Syrjanen KJ. Neoplasia intra-epitelial cervical: Diagnóstico e Tratamento. Rev Bras Ginecol Obstet. 2005;27(7):425-33.
4. Anjos SJSB, Vasconcelos CTM, Franco ES, Almeida PC, Pinheiro AKB. Fatores de risco para câncer de colo do útero segundo resultados de IVA, citologia e cervicografia. Rev Esc Enferm USP. 2010;44(4):912-20.
5. Duarte SJH, Matos KF, Oliveira PJM, Matsumoto AH, Morita LHM. Fatores de risco para câncer cervical em mulheres assistidas por uma equipe de Saúde da Família em Cuiabá, MT, Brasil. Cienc Enferm. 2011;XVII(1):71-80.
6. Brasil. Ministério da Saúde. Prevenção do Câncer do Colo do Útero. Manual Técnico para Laboratórios. Brasília (DF): Ministério da Saúde; 2002.
7. Brasil. Ministério da Saúde. Secretaria de Políticas de Saúde e Secretaria de Assistência à Saúde. Portaria Conjunta n. 92, de 16 de outubro de 2001. Dispõe sobre o controle da qualidade do exame citopatológico. [acesso 2011 set 20]. Disponível em: [http://sna.saude.gov.br/legisla/legisla/tab_sia/SPS_SAS_PC92_01tab_sia.doc].
8. Brasil. Ministério da Saúde. Agência Nacional de Vigilância Sanitária. Resolução da Diretoria Colegiada – RDC n. 302. Dispõe sobre o Regulamento Técnico para Funcionamento de Laboratórios Clínicos, 2005. [acesso 2011 set 20]. Disponível em: [http:// bvsms.saude.gov.br/bvs/saudelegis/anvisa/2005/res0302_13_10_2005.html].
9. Wiener HG, Klinkhamer P, Schenck U, Arbyn M, Bulten J, Bergeron C, Herbert A. European guidelines for quality assurance in cervical cancer screening: recommendations for cytology laboratories. Cytopathol. 2007;18(2):67-78.
10. Zeferino LC. O desafio de reduzir a mortalidade por câncer do colo do útero. Rev Bras Ginecol Obstet. 2008;30(5):213-5.
11. Andrew A, Renshaw MD. Strategies for Improving Gynecologic Cytology Screening. Cancer Cytopathol. 2009;25(6):151-3.
12. Tavares SBN, Amaral RG, Manrique EJC, Souza NLA, Albuquerque ZBP, Zeferino LC. Controle da qualidade em citopatologia cervical: revisão da literatura. Rev Bras Cancerol. 2007;53(4):355-65.
13. Amaral RG, Zeferino LC, Hardy E, Westin MCA, Martinez EZ, Montenor EBL. Quality assurance in cervical smears: 100% rapid rescreening versus 10% random rescreening. Acta Cytol. 2005;49:244-8.
14. Michelow P, Mckee G, Hlongwane F. Rapid rescreening of cervical smears as a quality control method in a righ-risk population. Cytopathol. 2006;17(6):110-5.
15. Lee BCK, Lam SY, Todd W. Comparison of false negative rates between 100% rapid review and 10% random full rescreening as internal quality control methods in cervical cytology screening. Acta Cytol. 2009;53(5):271-6.
16. Hutchinson ML. Assessing the costs and benefits of alternative rescreening strategies. Acta Cytol. 1996;40:(1)4-8.
17. Sood N, Singh V. Evaluation of 100% rapid rescreening of cervical smears. Indian J Pathol Microbiol. 2009;52(4):495-7.
18. Dudding N, Hewer EM, Lancucki L, Rice S. Rapid Screening: a comparative study. Cytopathol. 2001;12(4):235-48.
19. Ferraz MGMC, Dall’Agnol M, Di Loreto C, Pirani WM, Utagawa ML, Pereira SM, et al. 100% rapid rescreening for quality assurance in a quality control program in a public health cytologic laboratory. Acta Cytol. 2005;49(6):639-43.
20. Montemor EBL, Roteli-Martins CM, Zeferino LC, Amaral RG, Fonsechi-Carvasan GA, Shirata NK, et al. Whole, Turret and step methods of rapid rescreening: Is there any difference in performance?. Diag Cytopathol. 2007;35(1):57-60.
21. Solomon D, Nayar R. Sistema Bethesda para citopatologia cervicovaginal. 2ª ed. Rio de Janeiro: Revinter; 2005.
22. SAS Institute Inc. SAS/STAT software changes and enhancements through release 8.2. Cary: SAS Institute; 1999-2001.
23. Manrique EJC, Amaral RG, Souza NLA, Tavares SBN, Albuquerque ZBP, Zeferino LC. A revisão rápida de 100% é eficiente na detecção de resultados falso-negativos dos exames citopatológicos cervicais e varia com a adequabilidade da amostra: uma experiência no Brasil. Rev Bras Ginecol Obstet. 2007;29(8):402-7.
24. Diehl ARS e Prolla JC. Rapid rescreening of cervical smears for internal quality control. Acta Cytol. 1998;42(4):949-53.
25. Tavares SBN, Souza NLA, Manrique EJC, Albuquerque ZBP, Zeferino LC, Amaral RG. Comparation of the rapid prescreening, 10% random review, and clinical risk criteria as methods of internal quality control in cervical cytopathology. Cancer (Cancer Cytopathol). 2008;114(3):165-70.
26. Rama CH, Roteli-Martins CM, Derchain SFM, Longatto-Filho A, Gontijo RC, Sarian LOZ, et al. Prevalência do HPV em mulheres rastreadas para o câncer cervical. Rev Saúde Pública. 2008;42(1)123-30.
27. Mendes JC, Silveira LMS, Paredes AO. Lesão intraepitelial cervical: existe correlação entre o tempo de realização do exame de Papanicolaou e o aspecto do colo uterino para o aparecimento da lesão?. RBAC. 2004;36(4):191-6.
28. Moscicki AB, Shiboski S, Hills NK, Powell KJ, Jay N, Hanson EN, et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet. 2004;364(9446):1678-83.
29. Barcelos ACM, Michelin MA, Adad SJ, Murta EFC. Significado clínico do achado citológico de células escamosas atípicas de significado indeterminado. Femina. 2007;35(2):83-7.
30. Brasil. Ministério da Saúde. Rastreio de câncer cérvico-uterino em mulheres que têm ou tiveram DST. [acesso acesso 2011 set 20]. Disponível em: [http://www.aids.gov.br/assistencia/manualdst/item10.htm].
31. Diógenes MAR, Jorge RJB, Sampaio LRL, Mendonça FAC, Júnior RJ. Perfil de auxiliares e técnicas de enfermagem quanto aos fatores de risco para câncer cervical e adesão ao exame Papanicolaou. Rev APS. 2009;12(3):285-92.
32. Brasil. Ministério da Saúde. Instituto Nacional do Câncer. Diretrizes Brasileiras para o rastreamento do câncer do colo do útero. Rio de Janeiro: INCA; 2011. [acesso acesso 2011 set 20]. Disponível em [http://bvsms.saude.gov.br/bvs/controle_cancer].
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2012 Instituto Adolfo Lutz Journal